Oxford BioDynamics Yönetim

Yönetim kriter kontrolleri 2/4

Oxford BioDynamics CEO'su Jon Anthony Burrows, Mar2020 tarihinde atandı, in görev süresi 4.67 yıldır. in toplam yıllık tazminatı £ 606.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 55.4% maaş ve 44.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.5% ine doğrudan sahiptir ve bu hisseler £ 18.43K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5 yıl ve 5.6 yıldır.

Anahtar bilgiler

Jon Anthony Burrows

İcra Kurulu Başkanı

UK£606.0k

Toplam tazminat

CEO maaş yüzdesi	55.4%
CEO görev süresi	4.7yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	5yrs
Yönetim Kurulu ortalama görev süresi	5.6yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Watching Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Jan 18

Here's Why We're A Bit Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Oct 08

CEO Tazminat Analizi

Jon Anthony Burrows'un ücretlendirmesi Oxford BioDynamics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2024	n/a	n/a	-UK£11m
Dec 31 2023	n/a	n/a	-UK£11m
Sep 30 2023	UK£606k	UK£336k	-UK£11m
Jun 30 2023	n/a	n/a	-UK£10m
Mar 31 2023	n/a	n/a	-UK£8m
Dec 31 2022	n/a	n/a	-UK£7m
Sep 30 2022	UK£521k	UK£302k	-UK£7m
Jun 30 2022	n/a	n/a	-UK£7m
Mar 31 2022	n/a	n/a	-UK£6m
Dec 31 2021	n/a	n/a	-UK£7m
Sep 30 2021	UK£463k	UK£267k	-UK£7m
Jun 30 2021	n/a	n/a	-UK£6m
Mar 31 2021	n/a	n/a	-UK£5m
Dec 31 2020	n/a	n/a	-UK£5m
Sep 30 2020	UK£384k	UK£149k	-UK£4m

Tazminat ve Piyasa: Jon Anthony 'nin toplam tazminatı ($USD 783.00K ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 369.83K ).

Tazminat ve Kazançlar: Jon Anthony şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jon Anthony Burrows (62 yo)

4.7yrs

Görev süresi

UK£606,000

Tazminat

Dr. Jon Anthony Joseph Burrows, B.Sc. (Hons), M.Sc. & Ph D., serves as the Chief Executive Officer and Executive Director at Oxford BioDynamics Plc since March 23, 2020. He has been President of Contract S...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jon Anthony Burrows	CEO & Executive Director	4.7yrs	UK£606.00k	0.50% £ 18.4k
Paul Stockdale	CFO & Executive Director	7.2yrs	UK£239.00k	0.22% £ 7.9k
Alexandre Akoulitchev	Chief Scientific Officer & Executive Director	no data	UK£276.00k	2.27% £ 83.1k
Thomas Guiel	Chief Operating Officer	no data	Veri yok	0.26% £ 9.4k
David Blum	Senior Vice President of Marketing	no data	Veri yok	0.024% £ 873.6
Steven Arrivo	Senior Vice President of Business & Corporate Development	less than a year	Veri yok	Veri yok
Ewan Hunter	Chief Data Officer	5.4yrs	Veri yok	0.11% £ 4.2k
T. Demain	Company Secretary	no data	Veri yok	Veri yok

5.0yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: OBD 'un yönetim ekibi deneyimli ve deneyimlidir ( 5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jon Anthony Burrows	CEO & Executive Director	4.7yrs	UK£606.00k	0.50% £ 18.4k
Paul Stockdale	CFO & Executive Director	7.2yrs	UK£239.00k	0.22% £ 7.9k
Alexandre Akoulitchev	Chief Scientific Officer & Executive Director	17.4yrs	UK£276.00k	2.27% £ 83.1k
David Mark Holbrook	Independent Non-Executive Director	5.6yrs	UK£45.00k	0.016% £ 578.6
Edward Sikora	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stephen Diggle	Non-Executive Director	8.1yrs	UK£1.00	0.092% £ 3.3k
Iain McInnes	Member of Scientific Advisory Board	5.1yrs	Veri yok	Veri yok
Jane Mellor	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ooi Peng-Jin	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Matthew Wakefield	Independent Non-Executive Chairman	3.9yrs	UK£85.00k	0.45% £ 16.3k

5.6yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: OBD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).

Oxford BioDynamics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Oxford BioDynamics Plc, Annual General Meeting, Mar 27, 2024

Non-Executive Director recently sold UK£298k worth of stock

Non-Executive Director recently sold UK£52k worth of stock

Non-Executive Director recently bought UK£51k worth of stock

Oxford BioDynamics Plc, Annual General Meeting, Mar 30, 2023

Less than half of directors are independent

Recent updates

Oxford BioDynamics Publishes Study on Prognostic Covid Severity Test and Long COVID Analysis

New major risk - Market cap size

New major risk - Shareholder dilution

New major risk - Share price stability

First half 2024 earnings released: UK£0.023 loss per share (vs UK£0.032 loss in 1H 2023)

New major risk - Financial position

OBD Develops Multi-Cancer Diagnostic Test for Dogs

Oxford BioDynamics Plc to Report First Half, 2024 Results on Jun 18, 2024

Oxford BioDynamics Plc Opens Clinical Testing Facility in the UK to Perform EpiSwitch Prostate Screening (PSE) Blood Test

Oxford BioDynamics Plc has filed a Follow-on Equity Offering in the amount of £9 million.

Oxford BioDynamics Plc, Annual General Meeting, Mar 27, 2024

Here's Why We're Watching Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Full year 2023 earnings released: UK£0.073 loss per share (vs UK£0.067 loss in FY 2022)

Oxford BioDynamics Plc to Report Fiscal Year 2023 Results on Jan 17, 2024

New minor risk - Financial data availability

Non-Executive Director recently sold UK£298k worth of stock

Non-Executive Director recently sold UK£52k worth of stock

Oxford BioDynamics Plc Launches 94% Accurate PSE Test in US and UK

New major risk - Shareholder dilution

First half 2023 earnings released: UK£0.032 loss per share (vs UK£0.031 loss in 1H 2022)

Oxford BioDynamics Plc to Report First Half, 2023 Results on May 30, 2023

Oxford BioDynamics Plc Announces Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy for At Risk Men

Non-Executive Director recently bought UK£51k worth of stock

Full year 2022 earnings released: UK£0.067 loss per share (vs UK£0.072 loss in FY 2021)

Oxford BioDynamics Plc, Annual General Meeting, Mar 30, 2023

Oxford BioDynamics Plc Announces Initial Assessment of EpiSwitch Assay in Amyotrophic Lateral Sclerosis Trial

Less than half of directors are independent

Oxford BioDynamics Plc, Annual General Meeting, Oct 27, 2022

Here's Why We're A Bit Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Oxford BioDynamics plc Announces US Reimbursement Code for CiRT Now Available

First half 2022 earnings released

Oxford Biodynamics plc Checkpoint Inhibitor Response Test (Episwitch® Cirt) Now Available in the UK

Oxford BioDynamics Plc to Report First Half, 2022 Results on Jun 28, 2022

Oxford BioDynamics Plc Presents Additional Data at ASCO 2022

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oxford BioDynamics Plc Announces Successful Clinical Validation and US Launch of its Checkpoint Inhibitor Response Test

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oxford BioDynamics Plc Provides Update on EpiSwitch CST and CiRT tests

Is Oxford BioDynamics (LON:OBD) In A Good Position To Invest In Growth?

First half 2021 earnings released: UK£0.033 loss per share (vs UK£0.022 loss in 1H 2020)

Oxford BioDynamics (LON:OBD) Is In A Good Position To Deliver On Growth Plans

Oxford BioDynamics Plc Publishes Results of Biomarker Discovery Program Being Used for Development of Its EpiSwitch Covid-19 Severity Test

Full year 2020 earnings released: UK£0.047 loss per share (vs UK£0.03 loss in FY 2019)

Full year 2020 earnings released: UK£0.047 loss per share (vs UK£0.03 loss in FY 2019)

Oxford BioDynamics Plc, Annual General Meeting, Mar 24, 2021

Oxford BioDynamics Plc to Report Fiscal Year 2020 Results on Jan 28, 2021

Oxford BioDynamics Plc Announces Retirement of Christian Hoyer Millar from Board of Directors

Oxford BioDynamics Plc to Expand Strategic Focus Beyond Biomarker Discovery to Development and Commercialization of Laboratory Tests

We're Not Very Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Rate

New 90-day low: UK£0.70

Oxford BioDynamics Announces Strategic Partnership with Boca Biolistics in Order to Advance Episwitch™ Disease Severity Program for COVID-19

New 90-day high: UK£1.05

New 90-day high - UK£0.92

New 90-day high - UK£0.91

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş